In the News

Mar 15, 2010

A Perspective on Cancer Drug Pricing and Volume

Oncology Business Review, March 2010

By Bryan Cote

Affording and delivering cancer treatments has become increasingly difficult as cost of healthcare continues to rise. In response to the rising cost issue, oncologists and payers are seeking an improved drug cost to therapy benefit ratio—one with greater patient advantage, therapeutic efficacy and outcomes in exchange for their cancer drug dollar. Many stakeholders have criticized manufacturers for lack of innovation and assume prices have been intentionally set high to ensure a return on investment, and also as a way to secure the monies needed to further product development.

IntrinsiQ provided data for therapy cost changes. To read more of the article, click here or contact